Clovis CO-3810-101 LIO-1 (gynecological cancers) - Clinical Trial
What is the Purpose of this Study?
We are doing this study to learn about the safety and effectiveness of the study drugs (lucitanib and nivolumab) in advanced or metastatic gynecological cancers.
Lucitanib is a drug that is designed to block growth factors that help tumor cells grow. Nivolumab is a drug that helps block cancer cell’s ability to hide and activate your immune system to attack cancer cells.
Advanced or recurrent gynecological cancers
Who Can Participate in the Study?
Adult women with advanced or metastatic gynecological cancers (ovarian, endometrial, and cervical)
What is Involved?
If you agree to be in this study you will :
-Get a 28-day supply of lucitanib, (Pill you take once a day)
-Get an IV infusion of nivolumab every 28 days
-Have blood taken
-May be asked for additional biopsy samples of your tumor
*You will continue to get the study drug until your disease no longer responds to the study drugs, side effects prevent further continuation of the study drugs, you decide to no longer participate, or the study closes.
*Long-term follow up will be made every 3 months until end (up to 3 years).